Illumina, Inc. (ILMN) SVP Sells $29,827.95 in Stock
Illumina, Inc. (NASDAQ:ILMN) SVP Charles Dadswell sold 145 shares of Illumina stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $205.71, for a total transaction of $29,827.95. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Charles Dadswell also recently made the following trade(s):
- On Thursday, August 3rd, Charles Dadswell sold 1,609 shares of Illumina stock. The shares were sold at an average price of $197.00, for a total transaction of $316,973.00.
- On Monday, July 3rd, Charles Dadswell sold 145 shares of Illumina stock. The shares were sold at an average price of $174.24, for a total transaction of $25,264.80.
Illumina, Inc. (NASDAQ ILMN) traded up 1.34% during mid-day trading on Thursday, reaching $210.20. 757,035 shares of the company were exchanged. The company’s 50 day moving average price is $191.38 and its 200-day moving average price is $178.42. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $211.27. The stock has a market capitalization of $30.69 billion, a price-to-earnings ratio of 42.17 and a beta of 0.81.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The business had revenue of $662 million during the quarter, compared to analysts’ expectations of $642.38 million. During the same quarter in the previous year, the company earned $0.86 EPS. The business’s revenue was up 10.3% on a year-over-year basis. On average, equities research analysts forecast that Illumina, Inc. will post $3.65 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Illumina, Inc. (ILMN) SVP Sells $29,827.95 in Stock” was reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/09/07/illumina-inc-ilmn-svp-sells-29827-95-in-stock.html.
A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in Illumina by 2.6% in the 2nd quarter. Vanguard Group Inc. now owns 9,904,340 shares of the life sciences company’s stock worth $1,718,601,000 after purchasing an additional 255,498 shares in the last quarter. Capital World Investors raised its stake in Illumina by 23.8% in the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after purchasing an additional 410,000 shares in the last quarter. TIAA CREF Investment Management LLC raised its stake in Illumina by 55.6% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after purchasing an additional 527,548 shares in the last quarter. Geode Capital Management LLC raised its stake in Illumina by 8.0% in the 1st quarter. Geode Capital Management LLC now owns 1,458,071 shares of the life sciences company’s stock worth $248,460,000 after purchasing an additional 107,941 shares in the last quarter. Finally, Winslow Capital Management LLC acquired a new stake in Illumina in the 2nd quarter worth about $211,584,000. Institutional investors and hedge funds own 93.34% of the company’s stock.
Several equities research analysts recently issued reports on ILMN shares. Deutsche Bank AG set a $175.00 price objective on shares of Illumina and gave the company a “hold” rating in a research note on Friday, July 28th. Canaccord Genuity raised shares of Illumina from a “hold” rating to a “buy” rating and boosted their target price for the stock from $170.00 to $215.00 in a research report on Monday, August 7th. Morgan Stanley reissued an “underweight” rating and set a $122.00 target price (up previously from $115.00) on shares of Illumina in a research report on Monday, July 10th. Vetr lowered shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 target price for the company. in a research report on Wednesday, June 21st. Finally, Barclays PLC reissued a “hold” rating and set a $150.00 target price on shares of Illumina in a research report on Wednesday, July 19th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $177.01.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.